Alzheimer’s disease (AD), is the most common form of dementia. There is no cure for the disease, which worsens as it progresses, and eventually leads to death. It was first described by German psychiatrist and neuropathologist Alois Alzheimer in 1906 and was named after him.
Most often, AD is diagnosed in people over 65 years of age, although the less-prevalent early-onset Alzheimer’s can occur much earlier. In 2006, there were 26.6 million sufferers worldwide. Alzheimer’s is predicted to affect 1 in 85 people globally by 2050.
Although AD develops differently for every individual, there are many common symptoms. Early symptoms are often mistakenly thought to be ‘age-related’ concerns, or manifestations of stress. In the early stages, the most common symptom is difficulty in remembering recent events. When AD is suspected, the diagnosis is usually confirmed with tests that evaluate behaviour and thinking abilities, often followed by a brain scan if available.
As the disease advances, symptoms can include confusion, irritability and aggression, mood swings, trouble with language, and long-term memory loss. As the sufferer declines they often withdraw from family and society. Gradually, bodily functions are lost, ultimately leading to death. Since the disease is different for each individual, predicting how it will affect the person is difficult. AD develops for an unknown and variable amount of time before becoming fully apparent, and it can progress undiagnosed for years. On average, the life expectancy following diagnosis is approximately seven years. Fewer than three percent of individuals live more than fourteen years after diagnosis.
Stem cell therapy will include three sessions of 1x intravenous (IV) infusion and 1x intrathecal (IT) injection, spaced 5-12 days apart. Safety assessment will include administration of adverse events questionnaires, physical exam, and blood test conducted at specified. In order to assess efficacy of therapy, neurological/neurocognitive assessments, quality of life assessments, blood inflammatory and AD biomarkers and MRI test will be conducted at specific intervals.
To find out more about how you may benefit from this stem cell research protocol, please complete our Contact Us form and one of our physicians will reach out to you for a private consultation.